GlassScriptPhysician profile
George A Carden
NPI 1083640510
$2,151.56
in general payments reported to CMS, 2019-2025
34 companies · $610 in 2025
The $610 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $350 · 2021: $304 · 2022: $143 · 2023: $57.04 · 2024: $265 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $932.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $315.98 | 2019-2025 | Zerbaxa, Dificid, Capvaxive |
| Pfizer INC. | $175.91 | 2021-2025 | |
| Abbvie INC. | $143.79 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.05 | 2019-2025 | Xifaxan |
| Allergan, INC. | $126.10 | 2019-2020 | |
| Amgen INC. | $121.22 | 2019-2024 | Repatha, Otezla |
| Insmed, INC. | $94.99 | 2020-2024 | Arikayce |
| Exact Sciences Corporation | $84.59 | 2024-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $84.47 | 2019-2025 | Veklury |
| Viiv Healthcare Company | $64.38 | 2021-2022 | |
| Astellas Pharma US INC | $63.14 | 2019-2020 | |
| Glaxosmithkline, LLC. | $58.68 | 2020-2025 | Shingrix |
| Novo Nordisk INC | $50.16 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.64 | 2024-2025 | |
| Shionogi INC | $49.17 | 2020-2025 | Fetroja |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $47.16 | 2023-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $44.95 | 2025 | Breztri |
| La Jolla Pharmaceutical Company | $40.80 | 2021 | |
| Janssen Pharmaceuticals, INC | $39.65 | 2019 | |
| Eisai INC. | $37.09 | 2020-2021 | |
| Tetraphase Pharmaceuticals, INC. | $33.33 | 2019 | |
| Paratek Pharmaceuticals, INC. | $32.68 | 2025 | Nuzyra |
| Organogenesis INC. | $29.66 | 2020-2021 | |
| Sanofi Pasteur INC. | $28.35 | 2025 | |
| Seqirus USA INC | $23.54 | 2025 | Flucelvax, Fluad |
| Lilly USA, LLC | $23.38 | 2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.99 | 2019 | |
| Sunovion Pharmaceuticals INC. | $21.90 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.62 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $18.94 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.78 | 2020 | |
| Ibsa Pharma INC. | $16.26 | 2022 | |
| Redhill Biopharma INC. | $15.20 | 2020 | |
| Ge Healthcare | $14.01 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Carden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.